Pinky you nailed fonix, but somebody has steered you wrong on ABTX.
ABTX HAS THREE (two are EXCLUSIVE) BIOTECH AGREEMENTS INCLUDING ONE WITH MYCOGEN WHO IS OWNED BY DOW AND IN ADDITION OWNS A 100 YEAR OLD RESEARCH FIRM. It has much to do with biotech and has 45% market share for distribution, germ plasm and processing to continue to make more deals in digestibility, nutrition and environmental controls for forage and turf as well as ancillary products of corn and soybean.
ABTX is cash flow positive with high management investment into the company and about 10% ownership, with an additional million dollar recent open market purchase of shares. It has a seasoned management team from other seed companies who have set up biotech in other seed sectors that have been already scooped up by the major chemical concerns. The assistant CFO is from Novartis, hmmmmm. ABTX is anything BUT a fraud.
Additionally, Merrill Lynch was signed to enhance shareholder value and will either get an equity partner as Pioneer or Mycogen did with one of the major companies (DOW, DUPONT, NOVARTIS, HOECHST,MONSANTO) or ABTX will be bought out completely.
ABTX is severely undervalued here, there are much better shorts out there. As last independent seed distributor not to link up with a major chemical concern, that looks to be around the corner. Look at the press releases lately from the major chemicals (DOW, DUPONT, MONSANTO, NOVARTIS) and you will see the race is on for market share. That is what ABTX has to offer.
A good argument could be made that ABTX is worth 4-6 times today's price to a major chemical/drug concern.To be short here could be very expensive.
Good Luck
LADY |
